Evommune CEO reports 28,138-share tax withholding in Form 4

Evommune, Inc. President and CEO, who is also a director, reported an automatic share withholding related to equity compensation.

Rhea-AI Filing Summary

Evommune, Inc. President and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/09/2025, 28,138 shares of Evommune common stock were disposed of at a reported price of $17.84 per share. The filing explains that these shares were withheld to cover the reporting person's tax withholding obligations upon the settlement of restricted stock units, rather than an open-market sale. After this tax withholding event, the reporting person beneficially owns 654,683 shares of Evommune common stock in direct ownership.

Insider Trade Summary

Exercise Price or Tax Liability: 28,138 shares

Exercise Price or Tax Liability 1 txn

Insider Pena Luis C.

Role President & CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	28,138	$17.84	$502K

Holdings After Transaction: Common Stock — 654,683 shares (Direct)

Footnotes (1)

1. F1. Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

FAQ

What insider transaction did Evommune (EVMN) report in this Form 4?

The Form 4 reports that on 12/09/2025, the President & CEO and director of Evommune, Inc. had 28,138 shares of common stock withheld at $17.84 per share to cover tax obligations tied to restricted stock unit settlement.

Did the Evommune (EVMN) CEO sell shares on the open market?

The explanation states that the 28,138 shares were withheld to satisfy tax withholding obligations in connection with the settlement of restricted stock units, indicating this was a tax-related withholding rather than an open-market sale.

How many Evommune (EVMN) shares does the reporting person own after this transaction?

Following the reported tax withholding transaction, the reporting person beneficially owns 654,683 shares of Evommune common stock, held in direct ownership.

What was the reported price for the Evommune (EVMN) shares in this Form 4?

The Form 4 shows the 28,138 common shares were reported at a price of $17.84 per share for the tax withholding transaction.

What is the role of the reporting person at Evommune (EVMN)?

The reporting person is identified as a Director and an Officer of Evommune, Inc., serving as President & CEO.

Was the Evommune (EVMN) Form 4 filed for one or multiple reporting persons?

The filing indicates that it is a Form filed by one reporting person, not a joint or group filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pena Luis C.

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1841 PAGE MILL ROAD, SUITE 100

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		F		28,138(1)	D	$17.84	654,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.